BioSpace News Archive

The regulator greenlit 55 new drugs last year, seven of which belonged to Pfizer, including an ulcerative colitis treatment and a migraine nasal spray—both acquired in multibillion-dollar buys.

Tome Biosciences has only been on the scene for a short time but on Tuesday notched an acquisition of CRISPR-based biotech Replace Therapeutics for $65 million upfront.

After reporting positive mid-stage results for its LSD-based therapy for generalized anxiety disorder, MindMed’s chief medical officer sat down with BioSpace to discuss the path forward.

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference.

SELLAS Life Sciences Group, Inc. provided a business update and will host a corporate webinar at 8:30 am ET.

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received approval in Turkey from the Ministry of Health to proceed with a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 09, 2024, at 1:30 PM PT.

ReCode Therapeutics today announced that a patient was treated with RCT1100, a novel mRNA-based therapy currently being evaluated in a Phase 1 study in patients with primary ciliary dyskinesia (PCD) caused by pathogenic mutations in the DNAI1 gene.

Protagonist Therapeutics, Inc. oday announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a presentation and host one-on-one meetings with investors at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on January 8-11, 2024.

Genascence Corporation today announced the initiation of its Phase 1b clinical trial of GNSC-001 for the treatment of knee osteoarthritis (OA) (DONATELLO).